Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Editas Medicine, Inc.EDIT · Entity 5502 | Chief Operating Officer | March 15, 2017 | March 17, 2017 |
| REGENXBIO Inc.RGNX · Entity 2211 | Director | May 29, 2026 | June 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Editas Medicine, Inc.
Report date March 15, 2017 · Filed March 17, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 117,788 |
Ending reported balance
After 2017-03-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-03-15 · Exercise / conversion · Acquired 1,000 · Balance 118,788 F1: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 13, 2016. Row 2 · 2017-03-15 · Sale · Disposed 1,000 · Balance 117,788 F1: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 13, 2016. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.65 · Expires 2025-04-14 | Direct | 30,461 |
Reported balance
After 2017-03-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-03-15 · Exercise / conversion · Disposed 1,000 · Balance 30,461 F1: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 13, 2016. F2: This option was granted on April 16, 2015 and is scheduled to vest over four years with 25% of the shares having vested on March 9, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through March 9, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 13, 2016.
F2: This option was granted on April 16, 2015 and is scheduled to vest over four years with 25% of the shares having vested on March 9, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through March 9, 2019.
REGENXBIO Inc.
Report date May 29, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,861 |
Reported balance
After 2026-05-29 transaction · row 1
1 source rowRow 1 · 2026-05-29 · Grant · Acquired 9,807 · Balance 28,861 F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.01 · Expires 2036-05-29 | Direct | 46,600 |
Reported balance
After 2026-05-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-29 · Grant · Acquired 46,600 · Balance 46,600 F2: The option will vest on May 29, 2027 subject to the continuous service of the optionee to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer.
F2: The option will vest on May 29, 2027 subject to the continuous service of the optionee to the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 29, 2026 Filed Jun 2, 2026 21:16 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to Buy) · Derivative | 46,600 | $0.00 Strike: $7.01 | $0.00 |
DisclosureSEC source: 0001658390-26-000001 · primarydocument.xml · derivative · entry 2 Glucksmann Alexandra · CIK 0001658390 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,600 Underlying: Common Stock · 46,600 shares Expires 2036-05-29 F2 · derivative.exercise_date: The option will vest on May 29, 2027 subject to the continuous service of the optionee to the Issuer. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 21:16 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 9,807 | $0.00 | $0.00 |
DisclosureSEC source: 0001658390-26-000001 · primarydocument.xml · nonDerivative · entry 1 Glucksmann Alexandra · CIK 0001658390 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,861 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:32 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to Buy) · Derivative | 39,815 | $0.00 Strike: $8.85 | $0.00 |
DisclosureSEC source: 0001562180-25-004349 · primarydocument.xml · derivative · entry 2 Glucksmann Alexandra · CIK 0001658390 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,815 Underlying: Common Stock · 39,815 shares Expires 2035-05-30 F2 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 31, 2024 subject to the continuous service of the optionee to the Issuer. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:32 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 7,768 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-004349 · primarydocument.xml · nonDerivative · entry 1 Glucksmann Alexandra · CIK 0001658390 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,054 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 1, 2026 subject to the continuous service of the recipient to the Issuer. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 20:42 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to Buy) · Derivative | 24,454 | $0.00 Strike: $14.35 | $0.00 |
DisclosureSEC source: 0001562180-24-004653 · primarydocument.xml · derivative · entry 2 Glucksmann Alexandra · CIK 0001658390 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,454 Underlying: Common Stock · 24,454 shares Expires 2034-05-31 F2 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 31, 2024 subject to the continuous service of the optionee to the Issuer. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 20:42 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 4,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-004653 · primarydocument.xml · nonDerivative · entry 1 Glucksmann Alexandra · CIK 0001658390 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,286 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 1, 2025 subject to the continuous service of the recipient to the Issuer. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 21:12 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to Buy) · Derivative | 17,892 | $0.00 Strike: $19.72 | $0.00 |
DisclosureSEC source: 0001562180-23-004891 · primarydocument.xml · derivative · entry 2 Glucksmann Alexandra · CIK 0001658390 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,892 Underlying: Common Stock · 17,892 shares Expires 2033-06-02 F2 · derivative.exercise_date: The option will vest in 12 equal monthly installments following June 2, 2023 subject to the continuous service of the optionee to the Issuer. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 21:12 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 3,486 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-004891 · primarydocument.xml · nonDerivative · entry 1 Glucksmann Alexandra · CIK 0001658390 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,496 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 1, 2024 subject to the continuous service of the recipient to the Issuer. Read SEC document |
| June 03, 2022 Filed Jun 7, 2022 20:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 15,324 | $0.00 Strike: $22.84 | $0.00 |
DisclosureSEC source: 0001562180-22-004876 · primarydocument.xml · derivative · entry 2 Glucksmann Alexandra · CIK 0001658390 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,324 Underlying: Common Stock · 15,324 shares Expires 2032-06-03 F2 · derivative.exercise_date: The option will vest in 12 equal monthly installments following June 3, 2022 while the optionee provides continuous service to the Issuer. Read SEC document |
| June 03, 2022 Filed Jun 7, 2022 20:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 3,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-004876 · primarydocument.xml · nonDerivative · entry 1 Glucksmann Alexandra · CIK 0001658390 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,010 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 1, 2023 while the recipient provides continuous service to the Issuer. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 20:19 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $35.52 | $0.00 |
DisclosureSEC source: 0001562180-21-004127 · primarydocument.xml · derivative · entry 1 Glucksmann Alexandra · CIK 0001658390 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-04 F1 · derivative.exercise_date: The option will vest in 12 equal monthly installments following June 4, 2021. Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 20:33 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $37.66 | $0.00 |
DisclosureSEC source: 0001562180-20-004065 · primarydocument.xml · derivative · entry 1 Glucksmann Alexandra · CIK 0001658390 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-05-29 F1 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 29, 2020. Read SEC document |
| May 31, 2019 Filed Jun 4, 2019 20:19 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $43.02 | $0.00 |
DisclosureSEC source: 0001562180-19-003292 · primarydocument.xml · derivative · entry 1 Glucksmann Alexandra · CIK 0001658390 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-05-31 F1 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 31, 2019. Read SEC document |
| May 25, 2018 Filed May 30, 2018 20:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $49.45 | $0.00 |
DisclosureSEC source: 0001562180-18-002712 · primarydocument.xml · derivative · entry 1 Glucksmann Alexandra · CIK 0001658390 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-05-25 F1 · derivative.exercise_date: The option will vest in equal monthly installments over the 36 months following May 25, 2018, with immediate full vesting in the event of a change in control. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 15:53 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | Exercise / conversionStock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0001179110-17-004785 · edgar.xml · derivative · entry 3 Glucksmann Alexandra · CIK 0001658390 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,461 Underlying: Common Stock · 1,000 shares Expires 2025-04-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 13, 2016. F2 · derivative.exercise_date: This option was granted on April 16, 2015 and is scheduled to vest over four years with 25% of the shares having vested on March 9, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through March 9, 2019. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 15:53 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 1,000 | $26.41 | $26,410.00 |
DisclosureSEC source: 0001179110-17-004785 · edgar.xml · nonDerivative · entry 2 Glucksmann Alexandra · CIK 0001658390 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,788 F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 13, 2016. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 15:53 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | Exercise / conversionCommon Stock | 1,000 | $0.65 | $650.00 |
DisclosureSEC source: 0001179110-17-004785 · edgar.xml · nonDerivative · entry 1 Glucksmann Alexandra · CIK 0001658390 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 13, 2016. Read SEC document |
| February 15, 2017 Filed Feb 16, 2017 23:39 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | Exercise / conversionStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0001179110-17-002572 · edgar.xml · derivative · entry 4 Glucksmann Alexandra · CIK 0001658390 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,461 Underlying: Common Stock · 6,000 shares Expires 2025-04-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 13, 2016. F2 · derivative.exercise_date: This option was granted on April 16, 2015 and is scheduled to vest over four years with 25% of the shares having vested on March 9, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through March 9, 2019. Read SEC document |
| February 15, 2017 Filed Feb 16, 2017 23:39 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 1,000 | $23.48 | $23,484.40 |
DisclosureSEC source: 0001179110-17-002572 · edgar.xml · nonDerivative · entry 3 Glucksmann Alexandra · CIK 0001658390 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,788 F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 13, 2016. Read SEC document |
| February 15, 2017 Filed Feb 16, 2017 23:39 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 5,000 | $20.00 | $100,000.00 |
DisclosureSEC source: 0001179110-17-002572 · edgar.xml · nonDerivative · entry 2 Glucksmann Alexandra · CIK 0001658390 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,788 F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 13, 2016. Read SEC document |
| February 15, 2017 Filed Feb 16, 2017 23:39 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | Exercise / conversionCommon Stock | 6,000 | $0.65 | $3,900.00 |
DisclosureSEC source: 0001179110-17-002572 · edgar.xml · nonDerivative · entry 1 Glucksmann Alexandra · CIK 0001658390 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 13, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.